Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
TNDM Stock Chart & Stats
$18.69
-$0.45(-1.21%)
At close: 4:00 PM EST
$18.69
-$0.45(-1.21%)
Day’s Range― - ―
52-Week Range$9.98 - $35.12
Previous CloseN/A
Volume336.73K
Average Volume (3M)1.18M
Market Cap
$1.28B
Enterprise Value$1.64B
Total Cash (Recent Filing)$319.11M
Total Debt (Recent Filing)$449.28M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Feb 19, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding67,802,360
10 Day Avg. Volume1,183,137
30 Day Avg. Volume1,175,339
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)8.96
Price to Sales (P/S)2.51
P/FCF Ratio472.08
Enterprise Value/Market Cap1.28
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit3.06
Enterprise Value/Ebitda-9.14
Forecast
1Y Price Target
$27.58Price Target Upside47.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
International ExpansionEarly-stage penetration outside the United States for pump and patch insulin delivery suggests meaningful international market opportunity as commercialization expands into new regions.
Product PipelineA growth-accelerating product cycle, highlighted by the Mobi Tubeless device that could be submitted for regulatory review, could materially increase prescriptions and revenue if clinical and approval milestones are achieved.
Profitability And Pricing TailwindsAnalyst modeling points to potential upside from pharmacy channel dynamics and international price-related tailwinds that could improve margins and support a profitability recovery.
Bears Say
Share Price VulnerabilitySubstantial recent gains in the share price raise the likelihood of a retracement when new corporate guidance is provided and investor sentiment adjusts.
U.S. Demand Recovery RiskManagement expects U.S. new starts to return to growth in 2026 after multi-year declines, creating downside risk if the recovery proves slower or weaker than projected.
Valuation And ExpectationsInitial expectations for company performance may be too high and appear reflected in the current stock price, increasing vulnerability if operational results miss forecasts.
Tandem Diabetes Care News
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $9.98 and its highest was $35.12 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $1.28B.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Feb 19, 2026 which is in 4 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Nov 06, 2025. The company reported -$0.313 earnings per share for the quarter, beating the consensus estimate of -$0.329 by $0.016.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.09.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 67,802,360 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.313 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went up 21.98%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.58 (47.57% Upside)
$27.58 (47.57% Upside)
Blogger Sentiment
Bullish
TNDM Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 682.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.20%
12-Months-Change
Fundamentals
Return on Equity
-109.73%
Trailing 12-Months
Asset Growth
-8.67%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
TNDM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Tandem Diabetes Care's earnings call for the third quarter of 2025 reflected significant achievements, including record sales and margin improvements, driven by strategic initiatives in pricing, product innovation, and pharmacy expansion. However, challenges remain in the form of competitive pressures on new pump starts and transition-related impacts in Europe. Overall, the highlights significantly outweigh the lowlights, suggesting a strong positive outlook.View all TNDM earnings summariesTNDM Revenue Breakdown
74.21% U.S.
25.79% International
TNDM Stock 12 Month Forecast
Average Price Target
$27.58
▲(47.57% Upside)
Technical Analysis
Ownership Overview
0.77% Insiders
24.49% Mutual Funds
19.48% Other Institutional Investors
30.38% Public Companies and Individual Investors